UNSPSC 51181622: Tiratricol

This classification denotes a thyroid agent with the molecular formula C14H9I3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29OQ9EU4R1, chemically known as 3,3,5-triiodothyroacetic acid but generally known as tiratricol, which bears US NIH Compound Identifier 5803. European Medicines Agency schedules Tiratricol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11116MIG.

UNSPSC 51181622 Tiratricol, a Commodity code, addresses state and local procurement of thyroid hormone replacement therapies and related pharmaceutical products supplied through cooperative purchasing alliances. State and local governments—including state health agencies, departments of administration, and facilities management offices—procure tiratricol and generic multi-source pharmaceuticals through cooperative agreements administered by multistate purchasing entities. The work involves establishing master contracts with pharmaceutical manufacturers and vendors for supply through authorized wholesalers, with vendors required to maintain cGMP and DSCSA compliance, provide comprehensive product data (NDC codes, SKUs, UPCs, strength, dosage form, packaging), and offer pricing flexibility through multiple structures (flat price, net price formats, WAC-minus). Participating jurisdictions—state facilities, local government entities, and subordinate healthcare systems—draw supply under these agreements at negotiated rates. Insurance requirements typically include commercial general liability ($5 million per occurrence), network security and privacy liability ($2 million), and professional liability ($2 million).

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for Generic Multi Source Pharmaceuticals and OTC Products with a response deadline of March 26, 2026. The solicitation seeks multiple contract awards from pharmaceutical manufacturers to supply participating state and local facilities across Minnesota and Oregon through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Products must be available by May 15, 2026, with awarded contracts effective July 1, 2026. Evaluation weighted price competitiveness at 75 percent, with the remainder divided among fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). The contract term runs two years for new responders with optional extensions, while incumbent amendments extend through June 30, 2028.